1. Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
- Author
-
Liu SY, Feng WN, and Wu YL
- Subjects
- Humans, Biomarkers, Tumor genetics, Circulating Tumor DNA blood, Circulating Tumor DNA genetics, Clinical Trials as Topic, Neoadjuvant Therapy methods, Carcinoma, Non-Small-Cell Lung immunology, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Non-Small-Cell Lung genetics, Immunotherapy methods, Lung Neoplasms immunology, Lung Neoplasms genetics, Lung Neoplasms therapy
- Abstract
As immunotherapy makes its way into the perioperative setting, a growing number of clinical trials are expanding the evidence base for resectable non-small cell lung cancer (NSCLC) management. Identifying the optimal treatment pattern-whether it's neoadjuvant, adjuvant, or a combination of both-is a crucial next step, particularly in pinpointing which patients benefit the most. This decision-making process requires a multi-disciplinary treatment team capable of utilizing tissue and plasma genomic testing to inform therapeutic choices. Leveraging the perioperative treatment platform, it remains pivotal to integrate circulating tumor DNA (ctDNA) monitoring into clinical trial design efficiently and provide clear guidance on treatment., Competing Interests: Declaration of interests Y.-L.W reports grants and personal fees from AstraZeneca, BMS, and Pfizer and personal fees from Boehringer Ingelheim, Eli Lilly, Hengrui, MSD, Sanofi, and Roche., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF